ClinicalTrials.gg

Program

tegoprubart

Also written as “AT-1501”, “Tegoprubart” and “AT-1501 IV Infusion”.

Its studies are mostly in Kidney Failure, Chronic · Diabetes Mellitus, Type 1 · Glomerulonephritis, IGA · Amyotrophic Lateral Sclerosis, led by 2 companies.

Furthest: phase 3, since Sep 16, 20268 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eledon Pharmaceuticals63 open or runningphase 3since Sep 16, 2026Aug 19, 2021Jan 2027phase 2 · NCT05027906
Anelixis Therapeutics20 open or runningphase 2since Mar 20, 2020Mar 20, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2020First study: phase 2 study in Amyotrophic Lateral SclerosisNew to Anelixis TherapeuticsAnelixis Therapeutics · NCT04322149 · 54 enrolled · United States, Canada
  2. Jan 10, 2021Phase 2 study in Diabetes Mellitus, Type 1Anelixis Therapeutics · NCT04711226 · Canada
  3. Aug 19, 2021Eledon Pharmaceuticals's first study: phase 2 study in Kidney Failure, ChronicNew to Eledon PharmaceuticalsEledon Pharmaceuticals · NCT05027906 · 48 planned · United States, Australia, Brazil and more
  4. Nov 8, 2021Phase 2 study in Glomerulonephritis, IGAEledon Pharmaceuticals · NCT05125068 · 24 enrolled · Australia, Croatia, Malaysia and more
  5. Jul 27, 2022Phase 2 study in Diabetes Mellitus, Type 1Eledon Pharmaceuticals · NCT05480657 · United States
  6. Aug 2, 2023Phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT05983770 · 127 enrolled · United States, Australia, Brazil and more
  7. Nov 6, 2023Phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT06126380 · 132 planned · United States, Australia, Brazil and more
  8. Sep 16, 2026Phase 3 study in Kidney Failure, ChronicPhase 3 reachedEledon Pharmaceuticals · NCT07835581 · 620 planned

Ahead

  1. Jan 2027Primary completion: phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT05027906
  2. Mar 2029Primary completion: phase 3 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT07835581
  3. Dec 2029Primary completion: phase 2 study in Kidney Failure, ChronicEledon Pharmaceuticals · NCT06126380

TargetBeta

CD40LG →read by rule
“CD40 ligand inhibitor”ChEMBL 37, by rule

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dazodalibepruleAmgenphase 39
dapirolizumab pegolruleUCBphase 38
ravagalimabruleAbbViephase 24
OPT101ruleop-t-llcphase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07835581Kidney Failure, Chronic3Not yet recruitingEledon PharmaceuticalsMar 2029620
NCT06126380Kidney Failure, Chronic · United States, Australia, Brazil and more2By invitationEledon PharmaceuticalsDec 2029132
NCT05983770Kidney Failure, Chronic · United States, Australia, Brazil and more2CompletedEledon PharmaceuticalsSep 11, 2025127
NCT05480657Diabetes Mellitus, Type 1 · United States2WithdrawnEledon PharmaceuticalsAug 20240
NCT05125068Glomerulonephritis, IGA · Australia, Croatia, Malaysia and more2TerminatedEledon PharmaceuticalsJul 31, 202324
NCT05027906Kidney Failure, Chronic · United States, Australia, Brazil and more2RecruitingEledon PharmaceuticalsJan 202748
NCT04711226Diabetes Mellitus, Type 1 · Canada2WithdrawnAnelixis TherapeuticsJun 20240
NCT04322149Amyotrophic Lateral Sclerosis · United States, Canada2CompletedAnelixis TherapeuticsMar 24, 202254

How it is read

Names in the registry

  • “AT-1501”, 6 entries
  • “Tegoprubart”, 1 entry
  • “AT-1501 IV Infusion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.